Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate

Hypertension Research

Volumn 34, Issue 10, 2011, Pages 1121-1126

  Nakagawa, Naoki ^a   Fujino, Takayuki ^a   Kabara, Maki ^a   Matsuki, Motoki ^a   Chinda, Junko ^a   Kikuchi, Kenjiro ^a,b   Hasebe, Naoyuki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b Hokkaido Junkanki Hospital   (Japan)

Author keywords

candesartan; combination therapy; controlled release nifedipine; estimated glomerular filtration rate; urinary albumin excretion

Indexed keywords

ALBUMIN; CANDESARTAN; CREATININE; NIFEDIPINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ESSENTIAL HYPERTENSION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY ALBUMIN EXCRETION; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION, RENAL; MALE; MIDDLE AGED; NIFEDIPINE; RISK FACTORS; TETRAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053538514     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.101     Document Type: Article

References (30)

1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
2. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl JMed 2001; 345: 861-869.
3. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431. (Pubitemid 35340538)
4. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H. The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier H, Zanchetti A. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-1187.
6. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S12-S154.
7. Hasebe N, Kikuchi K. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005; 23: 445-453. (Pubitemid 40279649)
8. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
9. European Society of Hypertension-European Society of Cardiology Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
10. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73: 1303-1309. (Pubitemid 351693145)
11. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Ingelheim B, Dagenais G, Sleight P, Anderson C, Investigators O. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. (Pubitemid 351522739)
12. Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang XY, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, Investigators O. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
13. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
14. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51: 742-748. (Pubitemid 351301529)
15. Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferatoractivated receptor-gamma activation. Biochem Biophys Res Commun 2009; 385: 269-272.
16. Matsui T, Takeuchi M, Yamagishi S. Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity. Biochem Biophys Res Commun 2010; 396: 566-570.
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
18. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372. (Pubitemid 30487492)
19. de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164: 2459-2464. (Pubitemid 39628073)
20. Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA. Renal outcomes with different fixeddose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181.
21. Sluiter HE, Wetzels JF, Huysmans FT, Koene RA. The natriuretic effect of the dihydropyridine calcium antagonist felodipine: a placebo-controlled study involving intravenous angiotensin II in normotensive volunteers. J Cardiovasc Pharmacol 1987; 10(Suppl 10): S154-S161.
22. Wetzels JF, Wiltink PG, Hoitsma AJ, Huysmans FT, Koene RA. Diuretic and natriuretic effects of nifedipine in healthy persons. Br J Clin Pharmacol 1988; 25: 547-553.
23. Mancini GB, Miller ME, Evans GW, Byington R, Furberg CD, Pitt B. Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT). Am J Cardiol 2002; 89: 1414-1416. (Pubitemid 34607784)
24. Shinoda E, Yui Y, Kodama K, Hirayama A, Nonogi H, Haze K, Sumiyoshi T, Hosoda S, Kawai C. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension 2005; 45: 1153-1158. (Pubitemid 40770320)
25. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008; 26: 1891-1900.
26. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300: 975-978. (Pubitemid 20144223)
27. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543-1549. (Pubitemid 350199443)
28. Ogawa S, Mori T, Nako K, Ito S. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res 2008; 31: 1147-1155.
29. Konoshita T, Makino Y, Kimura T, Fujii M, Wakahara S, Arakawa K, Inoki I, Nakamura H, Miyamori I. A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker. J Hypertens 2010; 28: 2156-2160.
30. Nguyen TT, Kaufman JS, Whitsel EA, Cooper RS. Racial differences in blood pressure response to calcium channel blocker monotherapy: a meta-analysis. Am J Hypertens 2009; 22: 911-917.